Prior notification of a concentration

(Case M.10657 - SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 123/08)

1. On 11 March 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— Samsung BioLogics Co. Ltd. ('Samsung BioLogics', South Korea), a company controlled by the Samsung Group (South Korea), and

— Samsung Bioepis Co. Ltd. ('Bioepis, South Korea'), a company currently jointly controlled by Biogen Therapeutics Inc. (USA) and Samsung BioLogics.

Samsung BioLogics will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Bioepis.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following:

— Samsung BioLogics is a company active in the development and manufacturing of biopharmaceutical products worldwide.

— Bioepis is a company active in the development and commercialisation of biosimilar medicines.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 ([2]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10657 - SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').
([2]) OJ C 366, 14.12.2013, p. 5.